Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.
Nuvation Bio Inc. (NUVB) hosted its Q1 2026 financial results and corporate update call on May 4, 2026, at 4:30 PM EDT. Robert DeVita, Vice President of Corporate Development and Investor Relations, opened the session, noting that a press release summarizing the quarter's results had been issued earlier that day. The release is available on the Investors section of the company's website at nuvation.com, as DeVita stated during the call: “Earlier today, we issued a press release summarizing our financial results for the quarter ending March 31, 2026, and provided a business update.”Key participants included Founder, President, CEO and Chairman David Hung, Chief Commercial Officer Colleen Sjogren, and CFO Philippe Sauvage. Analysts from firms such as Jefferies LLC, RBC Capital Markets, Clear Street LLC, Truist Securities, B. Riley Securities, TD Cowen, and JonesTrading joined the conference call.DeVita highlighted forward-looking statements on the call, covering the therapeutic and commercial potential of IBTROZI and safusidenib, plans for safusidenib development, future data presentations, anticipated product revenue components, expected milestone payments, and the company's cash runway. He cautioned that actual results may differ due to risks and uncertainties, directing listeners to the Form 10-Q filed with the U.S. Securities and Exchange Commission that day for full details.The call was recorded, with a replay available on Nuvation Bio's website.